Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Interest & Investment Income (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Interest & Investment Income data on record, last reported at $7.3 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 57.23% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $18.4 million, down 9.5%, while the annual FY2025 figure was $18.4 million, 9.5% down from the prior year.
  • Interest & Investment Income reached $7.3 million in Q4 2025 per OCUL's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $7.3 million in Q4 2025 and bottomed at $6000.0 in Q4 2021.
  • Average Interest & Investment Income over 5 years is $2.2 million, with a median of $980000.0 recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 91.37% in 2021, then skyrocketed 6950.0% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $6000.0 in 2021, then surged by 6950.0% to $423000.0 in 2022, then skyrocketed by 244.92% to $1.5 million in 2023, then soared by 220.15% to $4.7 million in 2024, then soared by 57.23% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $7.3 million in Q4 2025, $3.7 million in Q3 2025, and $3.5 million in Q2 2025.